Cargando…

Screening for BRCA2 mutations in 81 Dutch breast–ovarian cancer families

We have analysed 81 families with a history of breast and/or ovarian cancer for the presence of germline mutations in BRCA2 with a number of different mutation screening techniques. The protein truncation test (PTT) for exons 10 and 11 detected four different frame-shifting mutations in six of these...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peelen, T, Vliet, M van, Bosch, A, Bignell, G, Vasen, H F A, Klijn, J G M, Meijers-Heijboer, H, Stratton, M, Ommen, G-J B van, Cornelisse, C J, Devilee, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363204/ https://www.ncbi.nlm.nih.gov/pubmed/10638982 http://dx.doi.org/10.1054/bjoc.1999.0892

Ejemplares similares

Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2
por: Oldenburg, RA, et al.
Publicado: (2005)

Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients
por: Papelard, H, et al.
Publicado: (2000)

Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients
por: Bock, G H de, et al.
Publicado: (2001)

Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer
por: Verhoog, L C, et al.
Publicado: (2000)

Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features
por: Berns, E M J J, et al.
Publicado: (2001)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

Embryonic lethality in the Brca1-1700T mouse model suggests inhibition of p53-dependent pathways
por: Hohenstein, P, et al.
Publicado: (2000)

Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13.
por: Cleton-Jansen, A. M., et al.
Publicado: (1995)

BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients
por: Yazici, H, et al.
Publicado: (2000)

Interval cancers in the Dutch breast cancer screening programme
por: Fracheboud, J, et al.
Publicado: (1999)

Exome Sequencing of Germline DNA from Non-BRCA1/2 Familial Breast Cancer Cases Selected on the Basis of aCGH Tumor Profiling
por: Hilbers, Florentine S., et al.
Publicado: (2013)

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2019)

Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families
por: Osorio, A, et al.
Publicado: (2000)

Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations
por: Gonzalez, R, et al.
Publicado: (1999)

Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer
por: Steinmann, D, et al.
Publicado: (2001)

Routine vaccination for influenza and pneumococcal disease and its effect on COVID-19 in a population of Dutch older adults
por: Taks, Esther J.M., et al.
Publicado: (2023)

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations
por: Wang-Gohrke, S, et al.
Publicado: (1999)

Keyword index to Volume 81
Publicado: (1999)

Author index to Volume 81
Publicado: (1999)

Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients
por: Díez, O, et al.
Publicado: (1999)

Prevalence and clustering of health behaviours and the association with socio-demographics and mental well-being in Dutch university students
por: van Hooijdonk, Kirsten J.M., et al.
Publicado: (2023)

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2
por: Schuyer, M, et al.
Publicado: (2001)

A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families
por: Vahteristo, P, et al.
Publicado: (2001)

Investigating the decrease in participation in the Dutch cervical cancer screening programme: The role of personal and organisational characteristics
por: Aitken, Clare A., et al.
Publicado: (2021)

Identification of a founder BRCA2 mutation in Sardinia
por: Pisano, M, et al.
Publicado: (2000)

Validity of the Rotterdam Elderly Pain Observation Scale for institutionalised cognitively impaired Dutch adults
por: Boerlage, A. A., et al.
Publicado: (2021)

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
por: Foekens, J A, et al.
Publicado: (1999)

The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives
por: Sng, J-H, et al.
Publicado: (2000)

BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer
por: Southey, M C, et al.
Publicado: (1999)

Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2007)

Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa
por: Staff, S, et al.
Publicado: (2001)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
por: Vazina, A, et al.
Publicado: (2000)

Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
por: de Witte, J H, et al.
Publicado: (1999)

Reply: Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients
por: Nieuwenhuis, M H, et al.
Publicado: (2011)

Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients
por: Foekens, J A, et al.
Publicado: (1999)

Evidence of a founder BRCA1 mutation in Scotland
por: Liede, A, et al.
Publicado: (2000)

Identification of over- and undertreatment in the Dutch national cervical cancer screening program: A data linkage study at the hospital level
por: Vink, Maarten D., et al.
Publicado: (2023)

Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer
por: Witte, J H de, et al.
Publicado: (1999)

Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours
por: Witte, J H de, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_cbrco1pi7cnft8ohcojecpt193